𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B

✍ Scribed by Nao Kurashige; Naoki Hiramatsu; Kazuyoshi Ohkawa; Takayuki Yakushijin; Shinichi Kiso; Tatsuya Kanto; Tetsuo Takehara; Akinori Kasahara; Yoshinori Doi; Akira Yamada; Masahide Oshita; Eiji Mita; Hideki Hagiwara; Toshihiko Nagase; Harumasa Yoshihara; Eijiro Hayashi; Yasuharu Imai; Michio Kato; Takeshi Kashihara; Norio Hayashi

Book ID
106180465
Publisher
Springer Japan
Year
2009
Tongue
English
Weight
321 KB
Volume
44
Category
Article
ISSN
0944-1174

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mutations associated with the therapeuti
Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis
✍ Kazuyoshi Ohkawa; Tetsuo Takehara; Michio Kato; Aimi Kanada; Matsuo Deguchi; Mas 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB

## Abstract Factors influencing the therapeutic efficacy of adefovir dipivoxil added to continuing lamivudine have not been elucidated in lamivudine‐resistant patients with type B chronic hepatitis. The viral mutations influencing the efficacy of treatment with adefovir dipivoxil were investigated

Clinical course and predictive factors o
Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients
✍ Mashu Aizawa; Akihito Tsubota; Kiyotaka Fujise; Keiko Tatsuzawa; Midori Kono; Sa 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views

## Abstract The aims of this study were to assess the long‐term efficacy of lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy in patients with chronic hepatitis B resistant to LAM, to identify predictive factors of complete viral response (HBV‐DNA <2.6 log copies/ml at 12 months of

Efficacy of entecavir in patients with c
Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone
✍ Ju Hyun Shim; Dong Jin Suh; Kang Mo Kim; Young-Suk Lim; Han Chu Lee; Young-Hwa C 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB 👁 1 views

Entecavir (ETV) is currently recommended as a rescue therapy purely for adefovir (ADV)resistant chronic hepatitis B virus (HBV) infections. We evaluated the efficacy of ETV in patients who were resistant to lamivudine (LAM)/ADV sequential therapy and in those resistant to LAM monotherapy. Fifty LAM/

Association of lamivudine-resistant muta
Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B
✍ Choong Keun Cha; Hyeok Choon Kwon; Jae Youn Cheong; Sung Won Cho; Sun Pyo Hong; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

## Abstract Adefovir has a potent antiviral activity as a rescue treatment against lamivudine‐resistant strains. The aim of this study was to assess the patterns of lamivudine‐resistant mutations and their influence on the virologic response to adefovir rescue therapy in patients with lamivudine‐re